What is the current size of the enzymatic DNA synthesis market?

The market size of the enzymatic DNA synthesis is estimated at USD 565.9 million in 2027.

What is the projected value of the enzymatic DNA synthesis industry by 2036?

Enzymatic DNA Synthesis Market size was valued at USD 466.3 million in 2026 and is anticipated to grow at a 25.37% CAGR from 2027 to 2036, attaining USD 4.47 billion by 2036.

How is the shift toward synthetic biology workflows influencing demand for enzymatic DNA synthesis platforms in research and commercialization environments?

It is increasing reliance on high-precision DNA constructs that support rapid design-build-test cycles. Users prioritize sequence accuracy and faster iteration to reduce redesign loops, improve reproducibility, and enable automated workflows where synthesis quality directly impacts research and commercialization efficiency.

How are declining synthesis costs reshaping purchasing behavior and scale of DNA manufacturing adoption?

Lower costs are shifting procurement from project-based ordering to routine, high-volume usage across discovery and optimization workflows. Organizations are integrating DNA synthesis into internal high-throughput systems, enabling scalable, continuous construct generation rather than selective outsourcing.

Why do biopharmaceutical companies lead the enzymatic DNA synthesis market?

Biopharmaceutical Companies held a 51.1% market share in 2026, driven by recurring demand for custom DNA constructs in drug discovery, biologics development, and cell and gene therapy workflows requiring high synthesis quality and rapid turnaround.

Why is synthetic biology the fastest-growing application in the enzymatic DNA synthesis market?

Synthetic Biology led with a 38.74% share in 2026 and remains the fastest-growing application because it depends on efficient DNA design, rapid sequence creation, and flexible synthesis for high-throughput engineering and testing workflows.

Why does North America lead the enzymatic DNA synthesis market?

North America held a 52.82% market share in 2026, supported by strong biotechnology and genomics ecosystems, established research infrastructure, and steady demand from pharmaceutical, academic, and industrial laboratories.

What is driving rapid growth in the enzymatic DNA synthesis market across Asia Pacific?

Asia Pacific is projected to grow at a 28.16% CAGR, fueled by expanding life sciences investment, wider synthetic biology adoption, and increasing genomics research that supports broader commercial deployment.

Who are the leading players in the enzymatic DNA synthesis landscape?

Major players in the enzymatic DNA synthesis market include Twist Bioscience Corporation (United States), DNA Script SAS (France), Telesis Bio Inc. (United States), Molecular Assemblies, Inc. (United States), Evonetix Ltd. (United Kingdom), Ansa Biotechnologies, Inc. (United States), GenScript Biotech Corporation (China), Camena Bioscience Ltd. (United Kingdom), Kern Systems Inc. (United States).